Literature DB >> 1282075

A possible role of decreased relaxation mediated by beta-adrenoceptors in bladder outlet obstruction by benign prostatic hyperplasia.

T Tsujii1, H Azuma, T Yamaguchi, H Oshima.   

Abstract

1. To explore mechanisms of urinary obstruction in benign prostatic hyperplasia (BPH), the features of contraction and relaxation in human hyperplastic and non-hyperplastic (control) prostatic tissues were investigated for beta- and alpha 1-adrenoceptors by radioligand binding and in vitro isometric tension experiments. 2. Hyperplastic and control prostatic tissues had a similar number (per mg protein) of prazosin binding sites with similar affinities. Noradrenaline (NA) induced dose-dependent contraction in both tissues. Contraction induced by either exogenous NA or transmural stimulation was inhibited by prazosin in both tissues, indicating that the same contractile mechanisms mediated by alpha 1-adrenoceptors exist in hyperplastic and control tissues. 3. The number of dihydroalprenolol (DHA) binding sites (per mg protein) was less in hyperplastic tissues than in controls, whereas the affinity to the ligand was identical in both tissues. Isoprenaline caused a marked relaxation of the tonic contraction induced by KCl in control tissues, but not in hyperplastic tissues. Propranolol enhanced exogenous NA- or transmural stimulation-induced contraction more in control tissues than in hyperplastic tissues. Both tissues, however, similarly responded to forskolin by relaxation. 4. These results indicate that decreased beta-adrenoceptor-mediated relaxation in hyperplastic prostatic tissues, which is attributable at least in part to the decreased number of beta-adrenoceptors, may play a role in the urinary obstruction of BPH in addition to mechanical compression of the urethra by the enlarged prostate.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1282075      PMCID: PMC1907759          DOI: 10.1111/j.1476-5381.1992.tb14527.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  12 in total

1.  Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck.

Authors:  M Caine; S Raz; M Zeigler
Journal:  Br J Urol       Date:  1975-04

2.  [Quantitation of alpha-1 and beta adrenergic receptor densities in the human normal and hypertrophied prostate].

Authors:  E Yokoyama; S Furuya; Y Kumamoto
Journal:  Nihon Hinyokika Gakkai Zasshi       Date:  1985-03

3.  The present role of alpha-adrenergic blockers in the treatment of benign prostatic hypertrophy.

Authors:  M Caine
Journal:  J Urol       Date:  1986-07       Impact factor: 7.450

4.  Alpha-1 adrenoceptors in human prostate: characterization and alteration in benign prostatic hypertrophy.

Authors:  S Yamada; N Ashizawa; H Ushijima; K Nakayama; E Hayashi; K Honda
Journal:  J Pharmacol Exp Ther       Date:  1987-07       Impact factor: 4.030

5.  Autonomic receptors in human prostate adenomas.

Authors:  D I Gup; E Shapiro; M Baumann; H Lepor
Journal:  J Urol       Date:  1990-01       Impact factor: 7.450

6.  [Pharmacological characteristics of smooth muscle in prostatic hyperplastic nodule and significance of clinical aspects].

Authors:  S Kitada
Journal:  Nihon Hinyokika Gakkai Zasshi       Date:  1983-12

7.  Contractile properties of human prostate adenomas and the development of infravesical obstruction.

Authors:  D I Gup; E Shapiro; M Baumann; H Lepor
Journal:  Prostate       Date:  1989       Impact factor: 4.104

8.  Alpha-adrenoceptors and muscarinic receptors in the isolated human prostate.

Authors:  H Hedlund; K E Andersson; B Larsson
Journal:  J Urol       Date:  1985-12       Impact factor: 7.450

9.  Effect of norepinephrine and isoproterenol on in vitro detrusor muscle contractility and cyclic AMP content.

Authors:  T J Rohner; J Hannigan
Journal:  Invest Urol       Date:  1980-01

10.  Characterization of alpha1 adrenergic receptors in human benign prostatic hyperplasia.

Authors:  H Lepor; E Shapiro
Journal:  J Urol       Date:  1984-12       Impact factor: 7.450

View more
  9 in total

1.  Intimal hyperplasia in human uterine arteries accompanied by impaired synergism between prostaglandin I2 and nitric oxide.

Authors:  S Obayashi; T Aso; J Sato; H Hamasaki; H Azuma
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

Review 2.  Novel drug targets for the pharmacotherapy of benign prostatic hyperplasia (BPH).

Authors:  S Ventura; V l Oliver; C W White; J H Xie; J M Haynes; B Exintaris
Journal:  Br J Pharmacol       Date:  2011-07       Impact factor: 8.739

3.  Nitric oxide based influence of nitrates on micturition in patients with benign prostatic hyperplasia.

Authors:  T Klotz; M J Mathers; W Bloch; W Nayal; U Engelmann
Journal:  Int Urol Nephrol       Date:  1999       Impact factor: 2.370

4.  Lower urinary tract symptoms, pain and quality of life assessment in chronic non-bacterial prostatitis patients treated with alpha-blocking agent doxazosin; versus placebo.

Authors:  Yalçin Evliyaoğlu; Refik Burgut
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

Review 5.  Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate.

Authors:  Martin C Michel; Wim Vrydag
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

6.  Role of endothelium in the human uterine arteries during normal menstrual cycle.

Authors:  H Azuma; S Obayashi; H Hamasaki; T Koyama; T Aso
Journal:  Br J Pharmacol       Date:  1995-02       Impact factor: 8.739

Review 7.  Role of α- and β-adrenergic signaling in phenotypic targeting: significance in benign and malignant urologic disease.

Authors:  M Archer; N Dogra; Z Dovey; T Ganta; H-S Jang; J A Khusid; A Lantz; M Mihalopoulos; J A Stockert; A Zahalka; L Björnebo; S Gaglani; M R Noh; S A Kaplan; R Mehrazin; K K Badani; P Wiklund; K Tsao; D J Lundon; N Mohamed; F Lucien; B Padanilam; M Gupta; A K Tewari; N Kyprianou
Journal:  Cell Commun Signal       Date:  2021-07-20       Impact factor: 5.712

8.  Observational study: daily treatment with a new compound "Tradamixina" plus serenoa repens for two months improved the lower urinary tract symptoms.

Authors:  Fabrizio Iacono; Domenico Prezioso; Ester Illiano; Antonio Ruffo; Giuseppe Romeo; Bruno Amato
Journal:  BMC Surg       Date:  2012-11-15       Impact factor: 2.102

Review 9.  Age-related changes in the innervation of the prostate gland: implications for prostate cancer initiation and progression.

Authors:  Carl W White; Jin Han Xie; Sabatino Ventura
Journal:  Organogenesis       Date:  2013-05-14       Impact factor: 2.500

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.